Global Pharmaceuticals Leader Committed to Ukraine Market

Teva Pharmaceuticals

Global pharmaceuticals group Teva, headquartered in Israel, is now ranked the biggest producer of generic pharmaceuticals in the world and is active in 60 countries. Teva Pharmaceuticals is committed to increasing access to high quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics.

Teva has been active in Ukraine for more than a decade and has steadily grown over the years through mergers and acquisitions to become a leader in the national pharmaceuticals sector, holding a 3% market share. Teva Ukraine expects to continue to grow rapidly. Alexandra Sologub, General Manager, explains, “Teva launched operations in Ukraine as a representative office specialising in oncology products. As Teva integrated other companies in Ukraine, we diversified and enlarged our business. Today, Teva Ukraine not only serves the local market but is also Teva’s hub for exports to Moldova, Georgia, Azerbaijan and Armenia.”

Teva Ukraine serves as a benchmark for high quality in Ukraine’s pharmaceuticals sector. As a rule Teva pharmaceuticals products are produced in compliance with GMP requirements, that has been confirmed by leading regulatory authorities of the industry, e.g. FDA, MHRA and others.

Teva Ukraine offers a full range of pharmaceuticals products, including over the counter (OTC) medicines, drugs for hospitals, and generic and special prescription pharmaceuticals in the areas of cardiology, pulmonology, neurology, psychiatry, gastroenterology, hematology, infectious diseases, oncology and others. Teva Ukraine will continue to expand its product portfolio to increase availability of quality treatment at an affordable price for Ukrainian consumer. Teva Ukraine benefits from its in depth understanding of the local market combined with the expertise of the international Teva group.

A challenge in Ukraine’s pharmaceuticals market, which is dominated by generic products, is a lack of reimbursement for pharmaceuticals purchases. Some patients have health insurance, but definitely not a majority. “When Ukraine introduces reimbursement for pharmaceuticals products, our market will definitely change,” Alexandra Sologub points out.

Teva has made a long term commitment to Ukraine, where it supports a number of corporate social responsibility projects. Alexandra Sologub concludes, “Corporate social responsibility is very important for Teva Ukraine.”